This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Mar;12(3):206-7.

doi: 10.1016/S1470-2045(11)70029-8.

Development of targeted therapies for pancreatic cancer

Philip A Philip¹

Affiliations

PMID: 21306954
DOI: 10.1016/S1470-2045(11)70029-8

Comment

Development of targeted therapies for pancreatic cancer

Philip A Philip. Lancet Oncol. 2011 Mar.

. 2011 Mar;12(3):206-7.

doi: 10.1016/S1470-2045(11)70029-8.

Author

Philip A Philip¹

Affiliation

¹ Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. philipp@karmanos.org

PMID: 21306954
DOI: 10.1016/S1470-2045(11)70029-8

No abstract available

PubMed Disclaimer

Comment on

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E. Kindler HL, et al. Lancet Oncol. 2011 Mar;12(3):256-62. doi: 10.1016/S1470-2045(11)70004-3. Lancet Oncol. 2011. PMID: 21306953 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information